Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.69 USD

127.69
1,121,487

-0.12 (-0.09%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.70 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

PacBio (PACB) and Form Bio to Boost AAV Industry Development

by Zacks Equity Research

PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.

Zacks Equity Research

Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Zacks Equity Research

Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down

by Zacks Equity Research

An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.

Zacks Equity Research

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Zacks Equity Research

Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care

by Zacks Equity Research

Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.

Zacks Equity Research

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Zacks Equity Research

BD's (BDX) New Research Tool to Aid Single-Cell Analysis

by Zacks Equity Research

BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.

Zacks Equity Research

Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Zacks Equity Research

DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.

Zacks Equity Research

Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Zacks Equity Research

Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices

by Zacks Equity Research

Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.

Zacks Equity Research

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Are Medical Stocks Lagging DaVita (DVA) This Year?

by Zacks Equity Research

Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Retain Inari Medical (NARI) for Now

by Zacks Equity Research

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Zacks Equity Research

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

by Zacks Equity Research

AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.

Zacks Equity Research

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on research and development raises optimism about the stock

Zacks Equity Research

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Zacks Equity Research

GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow

by Zacks Equity Research

GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.

Zacks Equity Research

GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities

by Zacks Equity Research

GE HealthCare's (GEHC) latest successful first installation and clinical cases using the OmnifyXR are likely to improve clinical and operational outcomes for both patients and clinicians.

Zacks Equity Research

Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments

by Zacks Equity Research

Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.

Zacks Equity Research

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.